Silexion Therapeutics Corp filed a Form 8-K on October 26, 2026, disclosing that shareholders approved two proposals at a reconvened extraordinary general meeting: an authorized share capital increase and a 1-for-24 reverse share split.

Key Highlights

  • Quorum met by rule: Holders of 2,697,489 ordinary shares, representing approximately 18.6% of issued and outstanding shares, were present; a quorum was constituted under Article 21.3 of the Articles after the lapse of a half hour from the scheduled commencement time.
  • Authorized share capital increase approved: Shareholders voted 2,567,677 in favor (95.4%) and 124,151 against (4.6%), with 5,661 abstentions, to increase authorized shares by 500,000,000, from 15,900,000 to 515,900,000 ordinary shares.
  • Reverse split approved: Shareholders voted 2,630,320 in favor (97.7%) and 61,787 against (2.3%), with 5,382 abstentions, authorizing a 1-for-24 consolidation of ordinary shares.
  • Par value change: Following the 1-for-24 reverse split, ordinary shares will carry a par value of $3.24 per share, up from $0.135 per share.
  • Capital structure after increase: Authorized share capital will rise from US$2,146,500 to US$69,646,500, according to the filing.
  • Memorandum Amendment effective October 26, 2026: The amendment to paragraph 5 of the Company's amended and restated memorandum of association was filed with the Registrar of Companies of the Cayman Islands and became effective that same day.

Silexion Therapeutics Reconvenes Meeting to Authorize Capital Changes and Reverse Split

According to the Form 8-K filed with the SEC on October 26, 2026, Silexion Therapeutics Corp (NASDAQ:SLXN) held an extraordinary general meeting that had originally convened on October 19, 2026 and was adjourned due to the absence of a quorum. When the meeting reconvened on October 26, 2026, the company reported that holders of 2,697,489 ordinary shares, or approximately 18.6% of issued and outstanding shares, were present. Under Article 21.3 of the Company's amended and restated articles of association, the shareholders then present constituted a quorum after the requisite waiting period.

The first proposal approved at the meeting authorizes an increase in the Company's share capital by 500,000,000 ordinary shares. The filing states that authorized share capital will increase from US$2,146,500, divided into 15,900,000 ordinary shares at a par value of US$0.135 each, to US$69,646,500, divided into 515,900,000 ordinary shares at the same par value. This proposal passed with 95.4% of votes cast in favor, excluding abstentions.

The second proposal granted the Board of Directors authority to effect a reverse share split within a range of 1-for-15 to 1-for-25, with the Board having determined a ratio of 1-for-24. The filing states that all issued and outstanding, and all authorized but unissued, ordinary shares with a par value of $0.135 will be consolidated on a 1-for-24 basis into a lesser number of ordinary shares with a par value of $3.24 per share. This proposal passed with 97.7% of votes cast in favor, excluding abstentions. The Company also holds warrants exercisable for ordinary shares listed on NASDAQ under the symbol SLXNW, with an exercise price of $15,525.00 per share, as noted in the filing's securities registration table.

What Was Disclosed

Silexion Therapeutics Corp disclosed shareholder approval of a 500,000,000-share authorized capital increase and a Board-determined 1-for-24 reverse share split at a reconvened extraordinary general meeting on October 26, 2026. The Memorandum Amendment became effective the same day upon filing in the Cayman Islands.